AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06449287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological Measures - ANAM
Description: The first cognitive assessment will be done via Automated Neuropsychological Assessment Metrics (ANAM). This cognitive battery is a library of computer-based tests of domains including attention, concentration, reaction time, memory, processing speed, decision-making, and executive function.
Study NCT06449287 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological Measures - ANAM
Description: The first cognitive assessment will be done via Automated Neuropsychological Assessment Metrics (ANAM). This cognitive battery is a library of computer-based tests of domains including attention, concentration, reaction time, memory, processing speed, decision-making, and executive function.
Study NCT01913132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy with PICO (Smith & Nephew)
Description: Negative wound pressure therapy
Study NCT01613469 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5FU/Leucovorin
Description: 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation (one cycle is the administration every day for 3 consecutive days, a cycle is 21 days)followed by 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles after completion of radiation.
Study NCT04389463 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No description
Study NCT04364048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Durvalumab
Description: Induction durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 1 cycle,
Study NCT04364048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion. The chemotherapy regimen used should be administered per institutional standards following the prescribing guidelines for each drug
Study NCT04364048 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons per institutional standards. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa). Therapy will be 1.8-2 Gy per day; 5 days per week, excluding holidays per institutional standard as this is a standard of care regimen for this patient population. 54-66 Gy will be delivered.
Study NCT04364048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation durvalumab
Description: Durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 12 cycles
Study NCT03091972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.
Study NCT03091972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.
Study NCT03091972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contact force assisted left atrial linear ablation
Description: Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation monitoring contact force.
Study NCT03091972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: left atrial linear ablation without contact force monitoring
Description: Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation without monitoring contact force.
Study NCT01097798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliviador
Description: The study medication should be applied regimen of 8/8 hours over 2 days.
Study NCT01097798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelol
Description: The study medication should be applied regimen of 8/8 hours over 2 days.
Study NCT02263131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG FLU Vaccine Prefilled Syringe INJ.
Description: IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL
Study NCT01707212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain management education
Description: Education about pain management during infant immunization
Study NCT01707212 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No pain management education
Description: Control - no education about pain management during infant immunization
Study NCT01043523 — intervention group
Intervention type: DRUG
Intervention: Gadoxetic Acid Disodium (Eovist, BAY86-4873)
Description: Participants have received Primovist/Eovist for liver Magnetic Resonance Imaging (MRI) as part of their routine care at participating institutions and additional diagnostic information are identified retrospectively from institution records
Study NCT02670551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Study NCT02670551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00987480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.
Description: There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.
Study NCT00987480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS device
Description: CD34+ T-cell depleted peripheral blood stem cell transplant
Study NCT06221124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belun Ring Pulse Oximeter
Description: Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Sleep stage (bSTAGES) and respiratory event index (bAHI) are estimated.
Study NCT03959150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral fluorouracil
Study NCT00534430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study NCT00534430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00534430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00534430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study NCT00534430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Study NCT00534430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT00534430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00534430 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Study NCT00566657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: riferminogene pecaplasmid
Description: Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid~Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated
Study NCT00566657 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for riferminogene pecaplasmid)
Description: Formulation: 5 ml glass vials containing 2,5 ml placebo~Route: IM injection of 2.5 mL in the ischemic leg to be treated
Study NCT03789630 — intervention group
Intervention type: DEVICE
Intervention: Continuous physiology monitoring in ambulatory setting pre and post surgery
Description: This study will recruit 55 patients aged 21 to 80 years who will be undergoing total knee replacement surgery. All study participants undergoing total knee replacement surgery will be monitored using the wearable biosensor to continuously monitor physiology biomarkers. Participants will be followed for an estimated total of 39 days, beginning four days before surgery, the entire period during in-patient recovery (four to five days), and 30-days post-discharge at-home.
Study NCT00397696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I] 5-IA
Description: All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of \[123I\] 5-IA followed by SPECT imaging as described below. A second \[123I\] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial \[123I\] 5IA imaging session.
Study NCT03058640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PKSA karate class
Description: Participants will attend at least 20/24 PKSA karate classes over a 12 week period, completing standard karate training lessons. Participants will also be encouraged to practice on their own at home.~• Participants must attend at LEAST 20/24 classes
Study NCT01581164 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza vaccine
Description: Influenza vaccine: Injection, post transplant
Study NCT01581164 — intervention group
Intervention type: BIOLOGICAL
Intervention: Varicella vaccine
Description: Varicella vaccine: Injection, post transplant
Study NCT01962298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex 2mg/kg
Study NCT01962298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Study NCT01962298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex 4mg/kg
Study NCT02263131 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAXIGRIP Prefilled Syringe INJ.
Description: VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL
Study NCT02925325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
Study NCT02925325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Treatment
Description: It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
Study NCT03624296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 7T
Description: MRI 7T
Study NCT03624296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST EDSS
Description: EDSS - Expanded Disability Status Scale
Study NCT03624296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST MSFC
Description: MSFC - Multiple Sclerosis Functional Composite
Study NCT04108676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: PARP inhibitor
Study NCT04108676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: proton pump inhibitor
Study NCT03649867 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interviews
Description: Each participant will attend a 30-45 minute semi-structured interview conducted by the CI
Study NCT03332550 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic lavage
Description: Operation with laparoscopic lavage for perforated diverticulitis Hinchey 3
Study NCT03332550 — intervention group
Intervention type: PROCEDURE
Intervention: Colon resection
Description: Operation with colon resection for perforated diverticulitis Hinchey 4
Study NCT02524210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: dabigatran etexilate 150 mg/day (1 day)
Study NCT02524210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole and Dabigatran
Description: rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;
Study NCT00678574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: Fluoxetine 20 mg daily by mouth for 2-3 months.
Study NCT00449787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan 100 mg
Description: Sumatriptan 100mg tablet
Study NCT00449787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg tablet
Study NCT01933516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP2013
Description: GP2013
Study NCT03702595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip flexors stretching protocol
Description: Stretching protocol of rectus femoris, vastus lateralis and iliopsoas according to Kaltenborn- Evjenth Orthopaedic Manual Therapy Concept (OMT)
Study NCT02062008 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET-MRI
Description: PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
Study NCT01901757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1201, Fasted followed by fed
Description: There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
Study NCT01901757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1201, Fed followed by fasted
Description: There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
Study NCT02156505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placement of double bare stent
Study NCT02156505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DoubleBare stent
Study NCT01423084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serogroup B meningococcal vaccine
Description: All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination
Study NCT01423084 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Serogroup B meningococcal vaccine
Description: All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination
Study NCT04226105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP40081
Description: 1 ml of the GP40081 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
Study NCT04226105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoMix 30
Description: 1 ml of the NovoMix 30 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
Study NCT02851511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (active stimulation)
Description: A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm x 7cm sponges (8cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (10-20 system).
Study NCT01963832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Study NCT02851511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (sham stimulation)
Description: Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
Study NCT02851511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Training
Description: Educational training involves watching educational videos produced by the National Geographic Channel, which cover a range of topics such as history, nature, and wildlife. Participants will be asked to complete questions on the content of the videos to ensure sustained attention.
Study NCT02029703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One Injection
Study NCT02029703 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Study NCT03909464 — intervention group
Intervention type: DEVICE
Intervention: Neurosensory testing with Pressure-Specified Sensory Device
Description: Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device.
Study NCT03566589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum PS128
Description: daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
Study NCT04394819 — intervention group
Intervention type: OTHER
Intervention: electromyography-triggered electrical stimulation
Description: All treatments were planned as 2 sessions per week, for a total of 10 sessions for 5 weeks. For EMG-trigger-ES application, dual-channel Nu-Tek® brand, Maxi plus 2 Model EMG-trigger-BF-ES Device in our clinic was planned to be used. With EMG-triggered-ES application, while the patient is in a sitting position, shoulder adduction, and the elbow is 90 degrees of flexion and pronation, the patient will extend to the ball of 5 cm in diameter, which is placed as far as the distance between the acromion and the 3rd toe, and then the finger-wrist active extension will be stimulated and then It was planned to apply the ball to be grasped. One of the two 5x5 cm superficial square electrodes of the device was planned to be placed on the extensor carpi radialis and extensor digitorum Communis and the other 2 cm distal.
Study NCT01954043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice a day (BID)
Description: Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29
Study NCT01954043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg once daily (OD)
Description: Rabeprazole dosed at 40mg each morning on Days 16 to 19
Study NCT01954043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg OD
Description: Rifampin dosed at 600mg each morning on Days 20 to 29
Study NCT03847168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026
Description: Patient will be intravenously administrated with one dose of KN026 every week or every other week.
Study NCT01285219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated filgrastim and ﬁlgrastim
Description: patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
Study NCT01285219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ﬁlgrastim and pegylated filgrastim
Description: patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2